• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在坦桑尼亚,接受基于多替拉韦的抗逆转录病毒方案治疗的 HIV 感染儿童和青少年的依从性、疗效和安全性。

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania.

机构信息

Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, 92976Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania.

Department of Pharmaceutics and Pharmacy practice, School of Pharmacy, 92976Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania.

出版信息

J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221109613. doi: 10.1177/23259582221109613.

DOI:10.1177/23259582221109613
PMID:35776522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9257168/
Abstract

This study aimed at assessing adherence, effectiveness, and safety of DTG-based HAART regimens among HIV-infected children and adolescents in Tanzania. This was a single-center prospective cohort study, conducted at the pediatric HIV Clinic in Mbeya, Tanzania. A binary logistic regression model was used to determine predictors of undetectable viral load at week 24. The results were significant when P-value was <0.05. A total of 200 patients were enrolled with the majority (85.5%) being treatment experienced. High adherence levels (71%) were observed using the pharmacy refill method. At week 24, the overall proportion of patients with undetectable viral load was 70.2%. The predictors of undetectable viral load were age, World Health Organization (WHO) clinical stage, baseline VL and adherence to pharmacy refill. The majority of patients attained undetectable viral load 6 months after using DTG based regimen. DTG-based regimens were generally safe with few ADEs reported.

摘要

本研究旨在评估坦桑尼亚感染艾滋病毒的儿童和青少年中基于 DTG 的 HAART 方案的依从性、疗效和安全性。这是一项单中心前瞻性队列研究,在坦桑尼亚姆贝亚的儿科 HIV 诊所进行。使用二元逻辑回归模型来确定在第 24 周时病毒载量不可检测的预测因素。当 P 值 <0.05 时,结果具有统计学意义。共有 200 名患者入组,其中大多数(85.5%)为治疗经验丰富者。使用药房补药方法观察到较高的依从性水平(71%)。在第 24 周,总体上有 70.2%的患者病毒载量不可检测。病毒载量不可检测的预测因素是年龄、世界卫生组织(WHO)临床分期、基线 VL 和对药房补药的依从性。大多数患者在使用基于 DTG 的方案后 6 个月达到了不可检测的病毒载量。基于 DTG 的方案通常是安全的,报告的不良药物反应(ADEs)很少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/c60f14bfd631/10.1177_23259582221109613-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/7160d90c80cd/10.1177_23259582221109613-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/a174dd1f21c9/10.1177_23259582221109613-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/b9fa9121f53c/10.1177_23259582221109613-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/c60f14bfd631/10.1177_23259582221109613-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/7160d90c80cd/10.1177_23259582221109613-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/a174dd1f21c9/10.1177_23259582221109613-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/b9fa9121f53c/10.1177_23259582221109613-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc34/9257168/c60f14bfd631/10.1177_23259582221109613-fig4.jpg

相似文献

1
Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania.在坦桑尼亚,接受基于多替拉韦的抗逆转录病毒方案治疗的 HIV 感染儿童和青少年的依从性、疗效和安全性。
J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221109613. doi: 10.1177/23259582221109613.
2
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.ODYSSEY 临床试验设计:一项全球性随机研究,旨在评估基于多替拉韦的抗逆转录病毒疗法在 HIV 阳性儿童中的疗效和安全性,并进行嵌套药代动力学子研究,以评估基于世界卫生组织实用体重区间的多替拉韦给药方案。
BMC Infect Dis. 2021 Jan 4;21(1):5. doi: 10.1186/s12879-020-05672-6.
3
Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV Following the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania.在坦桑尼亚达累斯萨拉姆引入多替拉韦方案后,HIV 感染者对艾滋病抗病毒治疗的坚持情况及其相关因素。
J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221084543. doi: 10.1177/23259582221084543.
4
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.多替拉韦治疗人类免疫缺陷病毒感染经治青少年的长期安全性和疗效:IMPACT P1093 研究结果。
J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):159-165. doi: 10.1093/jpids/piy139.
5
Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania.抗逆转录病毒疗法治疗下的艾滋病毒感染者青少年中病毒载量抑制的障碍:坦桑尼亚坦噶的一项回顾性研究。
AIDS Res Ther. 2024 May 22;21(1):35. doi: 10.1186/s12981-024-00622-7.
6
HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania.在使用多替拉韦的时代实现艾滋病毒病毒抑制:来自坦桑尼亚全国调查的结果。
PLoS One. 2024 Aug 14;19(8):e0307003. doi: 10.1371/journal.pone.0307003. eCollection 2024.
7
Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.在埃塞俄比亚,接受多替拉韦方案与依非韦伦方案的女性中病毒载量抑制情况:一项前后对照研究。
PLoS One. 2024 Jun 10;19(6):e0305331. doi: 10.1371/journal.pone.0305331. eCollection 2024.
8
Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.多替拉韦加拉米夫定作为初始治疗方案用于中国西部 HIV-1 感染且未接受过 ARV 治疗的患者:一项初步真实世界研究的 24 周结果。
Curr HIV Res. 2022;20(3):222-227. doi: 10.2174/1570162X20666220514165728.
9
Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.津巴布韦接受多拉韦林为基础的一线抗逆转录病毒治疗方案的患者的病毒学、体重和耐药性结果。
AIDS. 2024 Apr 1;38(5):689-696. doi: 10.1097/QAD.0000000000003830. Epub 2024 Jan 16.
10
Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi.马拉维儿童中基于多替拉韦的抗逆转录病毒方案扩大应用的早期效果。
AIDS Behav. 2024 Jun;28(6):2148-2155. doi: 10.1007/s10461-024-04312-3. Epub 2024 Apr 13.

引用本文的文献

1
Adherence to Dolutegravir-Based Antiretroviral Therapy and Its Associated Factors Among Children Living With HIV in Bahir Dar City Administration Public Health Institutions, North West Ethiopia.埃塞俄比亚西北部巴赫达尔市行政区公共卫生机构中感染艾滋病毒儿童对基于多替拉韦的抗逆转录病毒疗法的依从性及其相关因素
Sage Open Pediatr. 2025 Mar 12;12:30502225251314349. doi: 10.1177/30502225251314349. eCollection 2025 Jan-Dec.
2
Examining teen club attendance and viral load suppression among adolescents under differentiated HIV care in Malawi: a sub-optimal scenario.在马拉维接受差异化艾滋病毒治疗的青少年中,研究青少年俱乐部参与情况与病毒载量抑制:一种次优情况。
BMC Public Health. 2024 Dec 30;24(1):3605. doi: 10.1186/s12889-024-21109-0.
3

本文引用的文献

1
Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India.在印度西部一家大型三级护理诊所接受含仿制度鲁特韦治疗方案的患者的病毒学结果及低水平病毒血症发生率
Indian J Sex Transm Dis AIDS. 2021 Jan-Jun;42(1):31-37. doi: 10.4103/ijstd.IJSTD_34_20. Epub 2021 May 3.
2
Magnitude and associated factors of virological failure among children on ART in Bahir Dar Town public health facilities, Northwest Ethiopia: a facility based cross-sectional study.埃塞俄比亚西北部巴赫达尔镇公立卫生机构内接受抗逆转录病毒治疗的儿童中病毒学失败的程度及其相关因素:一项基于机构的横断面研究。
Ital J Pediatr. 2021 Apr 6;47(1):84. doi: 10.1186/s13052-021-01030-7.
3
Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania.
简短通讯:坦桑尼亚姆贝亚地区HIV研究参与者从依非韦伦转换为基于多替拉韦的抗逆转录病毒治疗的长期治疗结果
AIDS Res Ther. 2024 Dec 23;21(1):98. doi: 10.1186/s12981-024-00662-z.
4
Viral suppression and adherence in adolescents living with HIV in rural Tanzania.坦桑尼亚农村地区感染艾滋病毒青少年的病毒抑制情况及依从性
PLoS One. 2024 Dec 20;19(12):e0315866. doi: 10.1371/journal.pone.0315866. eCollection 2024.
5
HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania.在使用多替拉韦的时代实现艾滋病毒病毒抑制:来自坦桑尼亚全国调查的结果。
PLoS One. 2024 Aug 14;19(8):e0307003. doi: 10.1371/journal.pone.0307003. eCollection 2024.
6
Trends and correlates in HIV viral load monitoring and viral suppression among adolescents and young adults in Dar es Salaam, Tanzania.坦桑尼亚达累斯萨拉姆青少年和年轻成人中 HIV 病毒载量监测和病毒抑制的趋势及相关因素。
Trop Med Int Health. 2024 Sep;29(9):792-800. doi: 10.1111/tmi.14031. Epub 2024 Aug 4.
7
Adverse drug reactions, adherence, and virologic outcomes in adult patients on dolutegravir-based antiretroviral therapy at a tertiary hospital, southeast Nigeria.在尼日利亚东南部一家三级医院,接受多替拉韦为基础的抗逆转录病毒治疗的成年患者中的药物不良反应、依从性和病毒学结局。
Ghana Med J. 2024 Mar;58(1):101-108. doi: 10.4314/gmj.v58i1.14.
8
Prevalence and factors associated with viral non-suppression in people living with HIV receiving antiretroviral therapy in sub-Saharan Africa: A systematic review and meta-analysis.撒哈拉以南非洲地区接受抗逆转录病毒治疗的艾滋病毒感染者病毒抑制失败的流行情况及相关因素:系统评价和荟萃分析。
Rev Med Virol. 2024 May;34(3):e2540. doi: 10.1002/rmv.2540.
9
Virological Non-Suppression, Non-Adherence and the Associated Factors Among People Living with HIV on Dolutegravir-Based Regimens: A Retrospective Cohort Study.基于多替拉韦方案的HIV感染者的病毒学未抑制、不依从性及相关因素:一项回顾性队列研究
HIV AIDS (Auckl). 2024 Mar 21;16:95-107. doi: 10.2147/HIV.S449947. eCollection 2024.
10
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania.坦桑尼亚大陆开始使用多替拉韦为基础的抗逆转录病毒治疗的 HIV 感染者不良事件的发生率和决定因素。
Sci Rep. 2024 Jan 5;14(1):615. doi: 10.1038/s41598-023-51144-7.
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
简要报告:在当前治疗时代,ART 初治的 HIV 感染者在开始 ART 后体重增加。
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):339-343. doi: 10.1097/QAI.0000000000002556.
4
Factors Associated With Weight Gain in People Treated With Dolutegravir.多替拉韦治疗人群中与体重增加相关的因素
Open Forum Infect Dis. 2020 May 26;7(6):ofaa195. doi: 10.1093/ofid/ofaa195. eCollection 2020 Jun.
5
Outcomes of Integrase Inhibitor-based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection.基于整合酶抑制剂的抗逆转录病毒疗法在有 HIV 感染的治疗经验丰富的儿童、青少年和年轻成人临床队列中的结果。
Pediatr Infect Dis J. 2020 May;39(5):421-428. doi: 10.1097/INF.0000000000002577.
6
Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.多替拉韦/阿巴卡韦/拉米夫定单片方案在 HIV-1 成人感染患者真实队列中的疗效、安全性和成本。
Ann Pharmacother. 2020 Jul;54(7):633-643. doi: 10.1177/1060028019896638. Epub 2020 Jan 8.
7
Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.埃替格韦、多替拉韦和拉替拉韦在初治和经治患者真实世界队列中的安全性和有效性。
Medicine (Baltimore). 2019 Aug;98(32):e16721. doi: 10.1097/MD.0000000000016721.
8
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.基于多替拉韦的或基于低剂量依非韦伦的方案治疗人类免疫缺陷病毒 1 型。
N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24.
9
HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.HIV 感染者在美国接受治疗的时间内病毒抑制趋势:一项队列研究,1997 年至 2015 年。
Ann Intern Med. 2018 Sep 18;169(6):376-384. doi: 10.7326/M17-2242. Epub 2018 Aug 21.
10
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.多替拉韦用于中低收入国家的一线抗逆转录病毒治疗:实施和研究的不确定性和机遇。
Lancet HIV. 2018 Jul;5(7):e400-e404. doi: 10.1016/S2352-3018(18)30093-6. Epub 2018 Jun 5.